Compare Stocks: UPC, CVKD, TRAW, and ADXN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$5.66 -0.5%	$6.10	$5.04 ▼ $12.05	$6.97M	1.5	4,876 shs	2,105 shs
CVKD Cadrenal Therapeutics	$1.87 -4.6%	$3.02	$1.86 ▼ $14.64	$6.40M	1.84	61,400 shs	25,716 shs
TRAW Traws Pharma	$0.54 -2.7%	$0.83	$0.43 ▼ $3.27	$8.17M	1.57	1.09 million shs	52,270 shs
UPC Universe Pharmaceuticals	$6.24 +1.3%	$4.34	$2.00 ▼ $17.96	$3.51M	1.52	885,812 shs	88,996 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-9.81%	-9.07%	-14.54%	-23.93%	-38.69%
CVKD Cadrenal Therapeutics	-3.45%	-1.46%	-41.67%	-67.44%	-82.02%
TRAW Traws Pharma	+0.11%	+14.99%	-28.70%	-67.42%	-63.80%
UPC Universe Pharmaceuticals	-12.62%	+88.96%	+2.67%	+105.33%	+71.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$5.66 -0.5%	$6.10	$5.04 ▼ $12.05	$6.97M	1.5	4,876 shs	2,105 shs
CVKD Cadrenal Therapeutics	$1.87 -4.6%	$3.02	$1.86 ▼ $14.64	$6.40M	1.84	61,400 shs	25,716 shs
TRAW Traws Pharma	$0.54 -2.7%	$0.83	$0.43 ▼ $3.27	$8.17M	1.57	1.09 million shs	52,270 shs
UPC Universe Pharmaceuticals	$6.24 +1.3%	$4.34	$2.00 ▼ $17.96	$3.51M	1.52	885,812 shs	88,996 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-9.81%	-9.07%	-14.54%	-23.93%	-38.69%
CVKD Cadrenal Therapeutics	-3.45%	-1.46%	-41.67%	-67.44%	-82.02%
TRAW Traws Pharma	+0.11%	+14.99%	-28.70%	-67.42%	-63.80%
UPC Universe Pharmaceuticals	-12.62%	+88.96%	+2.67%	+105.33%	+71.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	1.00	Sell	N/A	N/A
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	595.19% Upside
TRAW Traws Pharma	1.60	Reduce	$1.00	85.53% Upside
UPC Universe Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest UPC, CVKD, TRAW, and ADXN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/6/2026	ADXN Addex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	UPC Universe Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Negative	$1.00
6/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$1.00
6/15/2026	TRAW Traws Pharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral
6/15/2026	TRAW Traws Pharma	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/29/2026	TRAW Traws Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
5/20/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$29.97K	232.65	N/A	N/A	$4.67 per share	1.21
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
TRAW Traws Pharma	$2.79M	2.93	$0.75 per share	0.72	($0.07) per share	-7.70
UPC Universe Pharmaceuticals	$17.74M	0.20	N/A	N/A	$99.64 per share	0.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$8.12M	-$5.94	N/A	N/A	N/A	N/A	-134.76%	-106.00%	8/24/2026 (Estimated)
CVKD Cadrenal Therapeutics	-$13.24M	-$5.63	N/A	N/A	N/A	N/A	-411.03%	-275.61%	8/10/2026 (Estimated)
TRAW Traws Pharma	$9.17M	-$1.69	N/A	N/A	N/A	N/A	-913.18%	-133.88%	8/13/2026 (Estimated)
UPC Universe Pharmaceuticals	-$3.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest UPC, CVKD, TRAW, and ADXN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TRAW Traws Pharma	-$0.3350	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	N/A	N/A	N/A	N/A	N/A
7/29/2026	Q2 2026	UPC Universe Pharmaceuticals	N/A	-$1.38	N/A	-$1.38	N/A	$4.52 million
5/15/2026	Q4 2025	TRAW Traws Pharma	-$0.92	-$0.53	+$0.39	-$0.53	$2.72 million	N/A
5/7/2026	Q4 2025	CVKD Cadrenal Therapeutics	-$1.51	-$1.04	+$0.47	-$1.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	0.97	0.97
CVKD Cadrenal Therapeutics	N/A	2.68	2.68
TRAW Traws Pharma	N/A	0.43	0.43
UPC Universe Pharmaceuticals	0.04	4.05	3.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
CVKD Cadrenal Therapeutics	7.92%
TRAW Traws Pharma	7.95%
UPC Universe Pharmaceuticals	0.18%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
CVKD Cadrenal Therapeutics	26.09%
TRAW Traws Pharma	7.57%
UPC Universe Pharmaceuticals	57.38%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.23 million	1.05 million	Not Optionable
CVKD Cadrenal Therapeutics	4	3.42 million	2.53 million	Not Optionable
TRAW Traws Pharma	17	15.15 million	14.00 million	No Data
UPC Universe Pharmaceuticals	220	563,000	240,000	N/A

UPC, CVKD, TRAW, and ADXN Headlines

Recent News About These Companies

Universe Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:UPC

July 18, 2026 | benzinga.com

Universe Pharmaceuticals INC - Ordinary Shares - Class A

July 17, 2026 | money.usnews.com

Universe Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:UPC | Benzinga

June 29, 2026 | benzinga.com

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

June 29, 2026 | markets.businessinsider.com

China's Universe Pharmaceuticals (NASDAQ: UPC) Makes Nasdaq Top Gainer List on Acquisition News

June 29, 2026 | investorideas.comI

Universe Pharmaceuticals INC.: Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

June 27, 2026 | finanznachrichten.de

Universe Pharmaceuticals Inc

June 26, 2026 | fool.com

UPC stock surges 288% after hours — what’s driving the rally?

June 26, 2026 | msn.com

Universe Pharmaceuticals to acquire Best Praise for $10.75M

June 26, 2026 | seekingalpha.com

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

June 26, 2026 | globenewswire.com

Universe Pharmaceuticals Stock News

June 17, 2026 | benzinga.com

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

June 16, 2026 | businesswire.com

Universe Pharmaceuticals Incorporation Class A

April 29, 2026 | edition.cnn.com

Universe Pharmaceuticals (NASDAQ:UPC) Stock Price Down 2.4% â€“ Time to Sell?

April 25, 2026 | defenseworld.netD

Universe Pharmaceuticals Sets February 13 Effective Date for Dual-Class Share Structure

February 11, 2026 | tipranks.com

Universe Pharmaceuticals INC Implements Dual-Class Share Structure on Nasdaq Effective February 13, 2026

February 11, 2026 | quiverquant.comQ

Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

February 11, 2026 | globenewswire.com

Universe Pharmaceuticals Inc trading resumes

October 8, 2025 | msn.com

Universe Pharmaceuticals Inc trading halted, volatility trading pause

October 8, 2025 | msn.com

Universe Pharmaceuticals Approves Key Resolutions at 2025 AGM

September 3, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

UPC, CVKD, TRAW, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$5.66 -0.03 (-0.53%)

Closing price 03:50 PM Eastern

Extended Trading

$5.62 -0.04 (-0.62%)

As of 04:04 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Cadrenal Therapeutics NASDAQ:CVKD

$1.87 -0.09 (-4.59%)

Closing price 04:00 PM Eastern

Extended Trading

$2.01 +0.14 (+7.54%)

As of 06:03 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Traws Pharma NASDAQ:TRAW

$0.54 -0.01 (-2.69%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 -0.01 (-2.60%)

As of 06:28 PM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Universe Pharmaceuticals NASDAQ:UPC

$6.24 +0.08 (+1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$6.26 +0.02 (+0.34%)

As of 06:46 PM Eastern

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPC, CVKD, TRAW, and ADXN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPC, CVKD, TRAW, and ADXN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPC, CVKD, TRAW, and ADXN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UPC, CVKD, TRAW, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Cadrenal Therapeutics NASDAQ:CVKD

Traws Pharma NASDAQ:TRAW

Universe Pharmaceuticals NASDAQ:UPC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UPC, CVKD, TRAW, and ADXN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UPC, CVKD, TRAW, and ADXN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UPC, CVKD, TRAW, and ADXN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UPC, CVKD, TRAW, and ADXN Company Descriptions

Addex Therapeutics NASDAQ:ADXN

Cadrenal Therapeutics NASDAQ:CVKD

Traws Pharma NASDAQ:TRAW

Universe Pharmaceuticals NASDAQ:UPC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools